medigraphic.com
ISSN 1025-0255 (Electronic)

2014, Number 2

<< Back Next >>

AMC 2014; 18 (2)

Resistance and sensibility to warfarin

Castelhanos RR, Ferrer HIM, Segura PLA, Ojeda MMR, Alfonso HMC

Language: Spanish
References: 41
Page: 226-239
PDF size: 151.12 Kb.


ABSTRACT

Background: warfarin is the most used oral anticoagulant in the world for treating the tromboembolic complications of prophylaxis that come with several cardiovascular diseases. Resistance to this medicine becomes a real health problem for those patients who need it.
Objective: to revise the different causes that can have an influence on a greater resistance and sensibility to warfarin.
Method: a bibliographic review in Scopus through HInari and in the BVS, in Scielo and in Medline through PubMed, was made. The following descriptors were used: warfarin, anticoagulant, resistance and sensibility, and contraindications. A total of 234 references were obtained; 94 of them were selected for this study. According to the type of reference, they included eight systematic reviews, four controlled clinical trials, and some observational studies and clinical case presentations. A bibliographical list that permitted the annotation of references was created.
Development: nowadays, warfarin is the anticoagulant mainly prescribed for the prevention and treatment of tromboembolic disorders in spite of being among the medicaments associate to a high incidence of undesirable effects. The most common and dangerous adverse reaction of warfarin is bleeding which may even be fatal; to this is added the interindividual variability in the response to the treatment; as well as its many pharmacological interactions. All these factors together can make of warfarin a difficult medicine to handle.
Conclusions: the high variability of these factors that may interfere with warfarin, make of this medicament one of the most difficult ones to handle. Diet, association 228 with other medicine and the genetic base of the patients are the factors that can mainly intervene in the resistance and sensibility to this medicament.


REFERENCES

  1. Quintero-González JA. Cincuenta años de uso clínico de la warfarina. Invest Clín. Jun 2010;51(2):23-7.

  2. Isaza C, Henao J, Beltrán L. Resistencia y sensibilidad a warfarina. Investigaciones Andina. 2010;1230-40.

  3. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV: The isolation and crystallization of the hemorrhagic agent. J Biol Chem. 1941;138:21-33.

  4. Campbell HA, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease. II: The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. J Biol Chem. 1941;138:1-20.

  5. Link KP. The discovery of dicumarol and its sequels. Circulation. 1959;19(1):97-107.

  6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.8th Ed. United State: Chest; 2008.

  7. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45(2):127-32.

  8. Alvarado I M. Manejo perioperatorio de la anticoagulación en pacientes tratados crónicamente con warfarina (con énfasis en la sustitución ambulatoria con heparinas de bajo peso molecular. Univ Med [Internet]. Jul-Sep 2012 [citado 18 Sep 2013];53(3):[aprox. 4 p.]. Disponible en: http://med.javeriana.edu.co/publi/vniversitas/serial/v53n3/5-Manejo%20perioperatorio.pdf

  9. Soto A, Cárcamo DA. Nuevos anticoagulantes orales en la prevención del ataque cerebrovascular. Rev Chil Neuro-Psiquiatr [Internet]. Dic 2012 [citado 13 Sep 2020];50(4):[aprox. 5 p.]. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext & pid=S0717-92272012000400006 & lng=es.

  10. Aristizábal JM, Restrepo AM, Uribe W, Medina E, Marín JE, Velásquez JE, et al. Consideraciones prácticas para el uso de los nuevos anticoagulantes orales. Rev Colomb Cardiol [Internet]. Jun 2012 [citado 20 Sep 2013];19(3):[aprox. 6 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext & pid=S0120-56332012000300006 & lng=en.

  11. Tan S, Zhou X, Li Z, Zhang W, Liu Z, Zhou H. Diagnosis and treatment of warfarin resistance. Zhong Nan Da Xue Xue Bao Yi Xue Ban [Internet]. 2013 Mar [cited 2012 Sep 13];38(3):[about 4 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/23545828.

  12. Tie JK, Jin DY, Tie K, Stafford DW. Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells. J Thromb Haemost [Internet]. 2013 Aug [cited 2012 Sep 12];11(8):[about 10 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/23710884.

  13. Fuchshuber-Moraes M, Perini JA, Rosskopf D, Suarez-Kurtz G. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: imxact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol. 2009;65(8):789-93.

  14. Yurgamy J, Rodriguez F. Warfarina: Uso contemporáneo. Rev Fac Med [Internet]. Ene 2009 [citado 13 Sep 2012];17(1):[aprox. 9 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext & pid=S0121-52562009000100015 & lng=es.

  15. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65(4):365-75.

  16. Kim Y, Smith A, Wu AH. C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta [Internet]. 2013 Jul [cited 2013 Sep 20];19(425C):[about 3 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/23872171

  17. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-63.

  18. Aithal GP, Day CP, Kesteven P, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1998;353:717-9.

  19. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-16.

  20. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-8.

  21. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5(3):193-202.

  22. Pchelina SN, Sirotkina OV, Taraskina AE, Vivalova TV, Shwarzman AL, Scwartz EI. The frequency of p450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thromb Res. 2005;115(3):199-203.

  23. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis. Genet Med. 2005;7(2):97-104.

  24. Visser L, Trienekens P, De Smet P, Vulto A, Hofman A, van Duijn C, et al. Patients with ApoE e4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics. 2005;15(2):69-74.

  25. Berrío M, Trujillo M, Vallejo Bi M, Barbosa HJ. Desarrollo y validación de una metodología analítica por HPLC-DAD para la cuantificación de Warfarina Sódica en una preparación extemporánea. Rev Colomb Cienc Quim Farm [Internet]. Jun 2013 [citado 18 Sep 2013];42(1):[aprox. 10 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext & pid=S0034-74182013000100008 & lng=en.

  26. Kohnke H, Sorlin K, Granath G, Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol. 2005;61(5-6):381-8.

  27. Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol. 2005;61(5-6):781-3.

  28. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin Pharmacol Ther. 2001;70(2):159-64.

  29. King B, Khan T, Aithal G, Kamali F, Daly A. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004;14(12):813-22.

  30. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest. 1996;98:1619-25.

  31. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-55.

  32. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N Engl J Med. 2005;352(22):2285-93.

  33. D´Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105(2):645-9.

  34. Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, et al. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis. J Thromb Haemost [Internet]. 2013 Feb [citado 2013 Sep 20];11(2):[about 9 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/23256818

  35. González-Juanatey JR, Álvarez-Sabin J, Lobos JM, Martínez-Rubio A, Reverter JC, Oyagüez I, et al. Análisis de coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España. Rev Esp Cardiol. 2012;65:901-10.

  36. Guyatt GH, Akl EA, Crowther M, Gutternau DD, Schuünemann MJ. Executive summary: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2012;141:7S-47S.

  37. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.

  38. Soto A, Cárcamo DA. Nuevos anticoagulantes orales en la prevención del ataque cerebrovascular. Rev chil Neuro-Psiquiatr [Internet]. Dic 2012 [citado 20 Sep 2013];50(4):[aprox. 5 p.]. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext & pid=S0717-92272012000400006 & lng=es.

  39. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al; for the AVERROES Steering Comité and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.

  40. Alvarado IM. Tendencias actuales en el manejo preoperatorio de pacientes anticoagulados con warfarina. Rev Colomb Anestesiol [Internet]. Apr 2012 [citado 20 Sep 2013];40(1):[aprox. 5 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext & pid=S0120-33472012000100010 & lng=en.

  41. Granger CB, Alexander AH, McMurray JJ, Lopes RD, Hylek EM, Han- na M, et al. Apixaban versus warfarin in patients with atrial fibrilla- tion. N Eng J Med. 2011;365:981-92.




2020     |     www.medigraphic.com